DALLAS, Feb. 11, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Athersys Inc. (Nasdaq:ATHX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/ATHX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Athersys Inc. (ATHX) is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates in multiple disease areas in the United States. Its product pipeline includes MultiStem, a patented and proprietary stem cell product candidate for the treatment of multiple disease indications. ATHX, through its product co-development collaboration with Angiotech Pharmaceuticals Inc., develops MultiStem for the treatment of damage caused by myocardial infarction and peripheral vascular disease, as well as for a range of disease indications, including ischemic injury and cardiovascular disease, certain neurological diseases, autoimmune diseases, transplant support, and various orphan disease indications. The Company is also in the process of developing novel pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness.
Message Board Search for ATHX: http://www.boardcentral.com/boards/ATHX
In the report, the analyst notes:
"Through the application of its proprietary technologies, ATHX has established a pipeline of therapeutic product development programs in multiple disease areas. The Company is committed to developing therapeutic products that it believes have best-in-class potential, meaning therapeutic candidates that have the potential to be safer, more effective products than the current standard of care or other products in development, and that may have other advantages, such as superior scalability or ease of administration.
"The Company recently announced it has been granted patents that cover its proprietary scalable MultiStem technology ... Both patents form part of ATHX's broad intellectual property portfolio of 14 granted patents and more than 120 global patent applications around its stem cell technology and MultiStem product platform, the report said."
To read the entire report visit: http://www.stockpreacher.com/n/ATHX
See what investors are saying about ATHX at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. StockPreacher.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.